In short
This article explores a clinical trial investigating the use of Suvecaltamide, a promising drug for treating moderate to severe residual tremor in adults with Parkinson's disease. The study aims to assess the efficacy and safety of Suvecaltamide in improving tremor symptoms that are not adequately controlled by standard Parkinson's medications and interfere with daily activities.
At a glance
- Study Drug
- Suvecaltamide (also known as JZP385, CX-8998, MK-8998)
- Target Condition
- Moderate to severe residual tremor in Parkinson's Disease
- Study Duration
- 23 weeks total (17 weeks treatment)
- Study Design
- Randomized, double-blind, placebo-controlled
- Dosing
- Flexible, 10-30 mg daily
- Primary Outcome Measure
- Change in TETRAS Composite Outcome Score
- Key Secondary Measures
- CGI-S, PGI-S, PGI-C, TETRAS-ADL, MDS-UPDRS Tremor Score
What is Suvecaltamide?
Suvecaltamide is an investigational drug that is currently being studied for its potential to treat tremor in people with Parkinson's disease. This medication is also known by other names, including JZP385, CX-8998, and MK-8998. It's important to note that as an investigational drug, suvecaltamide is not yet approved for general use and is still undergoing clinical trials to evaluate its safety and effectiveness.
What Condition Does Suvecaltamide Target?
Suvecaltamide is specifically being studied to treat moderate to severe residual tremor in adults with Parkinson's disease. Tremor is a common and often debilitating symptom of Parkinson's disease, characterized by involuntary shaking or trembling movements. "Residual tremor" refers to tremor that persists even when a person is taking standard Parkinson's medications. This persistent tremor can significantly interfere with a person's daily activities and quality of life.
How Does Suvecaltamide Work?
While the exact mechanism of action is not detailed in the provided information, suvecaltamide is being investigated as a potential treatment for tremor that is not adequately controlled by current Parkinson's disease medications. It's designed to target the tremor specifically, aiming to reduce its severity and improve the patient's ability to perform daily activities.
Current Clinical Trial
Suvecaltamide is currently being studied in a Phase 2 clinical trial. Here are some key details about this study:
- Duration: The trial lasts for 17 weeks, with a maximum total study duration of 23 weeks for each participant.
- Design: It is a randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to either receive suvecaltamide or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.
- Participants: The study includes adult participants with Parkinson's disease who have moderate to severe tremor that is not adequately controlled by their current medications.
- Study structure: The trial consists of a screening period (up to 4 weeks), a 5-week dose titration and optimization period, a 12-week maintenance period, and a 2-week safety follow-up period.
Dosage and Administration
In the clinical trial, suvecaltamide is administered as follows:
- It is taken orally (by mouth) once daily.
- The dose is gradually increased over time, starting at 10 mg per day and potentially increasing by 10 mg every 7 days.
- The maximum dose in the trial is 30 mg per day.
- The dose is adjusted based on how well it works and how well it's tolerated by each participant.
How is Effectiveness Measured?
The researchers are using several methods to measure how well suvecaltamide works. These include:
- TETRAS Composite Outcome Score: This is the primary measure used in the study. It combines assessments of how tremor affects daily activities and performance of specific tasks.
- Clinical Global Impression of Severity (CGI-S): This is a scale used by doctors to assess how severe the tremor's impact is on the patient's ability to function.
- Patient's Global Impression of Severity (PGI-S): This is similar to the CGI-S, but it's completed by the patients themselves.
- Patient's and Clinician's Global Impression of Change (PGI-C and CGI-C): These scales measure how much the patient's condition has changed since the start of the study.
- MDS-UPDRS Tremor Score: This is a more comprehensive assessment of various aspects of tremor in Parkinson's disease.
Potential Benefits
If successful, suvecaltamide could potentially offer several benefits for people with Parkinson's disease:
- Reduction in tremor severity, particularly for those whose tremor is not well-controlled by current medications.
- Improvement in the ability to perform daily activities that are affected by tremor, such as eating, drinking, dressing, and writing.
- Enhanced overall function and quality of life for people with Parkinson's disease who experience significant tremor.
It's important to remember that suvecaltamide is still in the testing phase, and more research is needed to confirm its safety and effectiveness. Patients interested in this treatment should discuss it with their healthcare providers and consider participating in clinical trials if appropriate.